Aastrom Biosciences ends drug trial, to cut half its workforce

March 27 Wed Mar 27, 2013 9:06am EDT

March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.

The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.

The company has about 71 employees, according to Thomson Reuters data.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.